Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acquisitions and olmesartan weakness to weigh on Daiichi Sankyo this year

This article was originally published in Scrip

Executive Summary

Daiichi Sankyo expects its sales to remain virtually static this fiscal year, held back by weakness for its top product olmesartan and the loss of exclusivity for levofloxacin in the US, along with a lower contribution from Indian unit Ranbaxy.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel